Navigation Links
Key Protein May Lead to Faster Acting Anti-Depression Drugs
Date:3/23/2009

NEW YORK, March 23 /PRNewswire-USNewswire/ -- Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University, Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal of Neuroscience that the brain protein called p11 could lead pharmaceutical companies to develop anti-depression drugs that begin working within hours or days rather than the weeks or even months required by current drugs.

This study, Role of p11 in Cellular and Behavior Effects of 5-HT4 Receptor Stimulation, solidifies the protein p11 as a key determinant of vulnerability to depression. This new research shows that p11 activates a serotonin receptor in the brain known for producing rapid antidepressant response.

"There is pressing clinical need for faster-acting antidepressants," says Greengard. "An understanding of the cellular mechanisms underlying the therapeutic actions of these drugs may lead to better treatments with fewer side effects." In fact, each year over 17 million American adults experience at least one episode of clinical depression. Depression experts claim that many people with a depressive illness never seek treatment. Perhaps if there were antidepressants available that could start working in hours or days rather than weeks or months, more people would seek treatment.

Previous research by Greengard, who was awarded the 2000 Nobel Prize in Medicine or Physiology, helped establish p11 as an important protein that regulates signaling in the brain by the neurotransmitter serotonin, which has long been linked to mood. Michael Stern Parkinson's Research Center scientists begun studying p11 because the serotonin system which is central to depression is connected to dopamine in Parkinson's disease.

The Michael Stern Parkinson's Research Foundation vision is a world without Parkinson's disease. To accomplish their vision, and cognizant that Parkinson's disease is the world's second most prevalent neurological disease after Alzheimer's, The Michael Stern Parkinson's Research Foundation mission is to fund promising, intensive, scientific and medical research that will delay Parkinson's onset, reduce the severity of its symptoms and provide better treatments, as well as fund research into related neurological diseases that can lead to a Parkinson's cure and, through education of health care professionals and the public, attempt to improve the quality of life of Parkinson's patients and their caregivers and families. www.ParkinsonInfo.org


'/>"/>
SOURCE The Michael Stern Parkinson's Research Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
2. Aiming at Multiple Alzheimers Proteins May be Key to Success
3. Protein Shown to Play a Key Role in Normal Development of Nervous System
4. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
5. The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
6. Protein Key to Control Growth of Blood Cells
7. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
8. Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies
9. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
10. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
11. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
Breaking Medicine Technology:
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):